Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart wave analysis may reveal hidden recovery in lung disease patients

NCT ID NCT07522203

Knowledge-focused Sponsor: Istanbul Mehmet Akif Ersoy Educational and Training Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a special heart pressure wave test can better track recovery in adults with chronic blood clots in the lungs (CTEPH) who are getting a procedure to open blocked arteries (balloon pulmonary angioplasty). Researchers will measure walking distance, heart function, and quality of life before and after treatment. The goal is to see if these new measurements are more useful than standard tests for showing true improvement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include consecutive patients with a confirmed diagnosis of CTEPH according to current guidelines who are clinical candidates for balloon pulmonary angioplasty (BPA).

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-85 years. Confirmed diagnosis of CTEPH by a multidisciplinary CTEPH team and deemed eligible for BPA. Hemodynamics compatible with pre-capillary PH according to current guidelines, as assessed by RHC (Right Heart Catheterization). Technically inoperable CTEPH or persistent/recurrent PH following PEA (Pulmonary Endarterectomy). Written informed consent. Exclusion Criteria: * Predominant diagnosis of PH other than CTEPH or concomitant severe parenchymal lung disease. Active infection, uncontrolled systemic disease, active malignancy, or life expectancy \< 12 months. Pregnant or lactating patients. Advanced renal failure (e.g., eGFR \< 30 \\text{ mL/min/1.73 m\^2}) or contraindications to contrast media (per institutional routine). Inadequate image quality precluding reliable echocardiographic analysis. Pressure tracings with significant artifacts hindering analysis or uncontrolled arrhythmia (e.g., atrial fibrillation with rapid ventricular response). Decompensated or hemodynamically unstable patients. Any other condition deemed clinically unsuitable by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CTEPH are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic thromboembolic pulmonary hypertension pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CTEPH Pulmonary hypertension (PH)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istanbul Mehmet Akif Ersoy Educational and Training Hospital

    RECRUITING

    Istanbul, 34303, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.